Nature Medicine· José Manuel Pérez-García·· 20 小时前AI 评分58
PHERGain 试验 5 年结果：HER2 阳性早期乳腺癌化疗降阶梯与 ctDNA 探索性分析
5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial
AI 导读
Nature Medicine 在线发表 PHERGain II 期试验的 5 年二次分析，结果支持在 HER2 阳性早期乳腺癌中采用 PET 引导的自适应策略进行降阶梯治疗。该分析同时给出循环肿瘤 DNA 的探索性结果，提示其可能为后续治疗决策提供参考。
正文 · 原文
Nature Medicine, Published online: 29 October 2026; doi:10.1038/s41591-026-04723-w
A 5-year secondary analysis of the phase 2 PHERGain trial supports the clinical utility of a PET-guided adaptive strategy for treatment de-escalation in HER2-positive early breast cancer and provides circulating tumor DNA insights that could inform further treatment approaches.
来源：Nature Medicine · nature.com